Advertisement
Survey Series
Institutions
For Advertisers
|
|
||||
|
New Frontiers in Commercialization
Universities need to make innovative moves to maximize the potential of intellectual property
Email: Edward R Burns - eburns@aecom.yu.edu The Scientist 2005, 19(1):41
|
||||
|
|
||||
|
Two decades ago, in the high-flying 1980s, there was great hope for licensing newly described molecules, compounds, and targets as potential diagnostic and therapeutic agents. Monoclonal antibodies, novel peptides, and other small molecules produced by academic researchers were quickly acquired by major pharmaceutical companies, emerging biotechnology companies, and startup ventures. The bubble burst not only because of general economy reversals, but also due to the realization that in the game of drug development, there were very few home runs.
|
|
|||||||||
|
|||||||||
|
